New hope for rare hormone disorder: Higher-Dose drug trial underway
NCT ID NCT07081997
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This study tests a daily injection of palopegteriparatide at doses above 30 mcg in adults with hypoparathyroidism, a condition where the body doesn't make enough parathyroid hormone. The goal is to see if higher doses can safely control calcium levels without needing extra vitamin D or calcium supplements. About 36 participants already on the drug will take part for 78 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ascendis Pharma Investigational Site
RECRUITINGReno, Nevada, 89511, United States
-
Ascendis Pharma Investigational Site
RECRUITINGNew York, New York, 10032, United States
-
Ascendis Pharma Investigational Site
RECRUITINGSpokane Valley, Washington, 99216, United States
Conditions
Explore the condition pages connected to this study.